Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease

BACKGROUND & AIMS: T-helper (Th)1 cells play a central role in the pathogenesis of tissue damage in Crohn's disease (CD). Interleukin (IL)-12/STAT4 signaling promotes Th1 cell commitment in CD, but other cytokines are needed to maintain activated Th1 cells in the mucosa. In this study, we examined the expression and role of IL-21, a T-cell-derived cytokine of the IL-2 family; in tissues and cells isolated from patients with inflammatory bowel disease. METHODS: IL-21 was examined by Western blotting in whole mucosa and lamina propria mononuclear cells (LPMCs) from patients with CD, ulcerative colitis (UC), and controls. We also examined the effects of exogenous IL-12 on IL-21 production, as well as the effects of blocking IL-21 with an IL-21-receptor Ig fusion protein. Interferon (IFN)-gamma was measured in the culture supernatants by enzyme-linked immunosorbent assay, and phosphorylated STAT4 and T-bet were examined by Western blotting. RESULTS: IL-21 was detected in all samples, but its expression was higher at the site of disease in CD in comparison with UC and controls. Enhanced IL-21 was seen in both ileal and colonic CD and in fibrostenosing and nonfibrostenosing disease. IL-12 enhanced IL-21 in normal lamina propria lymphocytes through an IFN-gamma-independent mechanism, and blocking IL-12 in CD LPMCs decreased anti-CD3-stimulated IL-21 expression. Neutralization of IL-21 in CD LPMC cultures decreased phosphorylated STAT4 and T-bet expression, thereby inhibiting IFN-gamma production. CONCLUSIONS: Our data suggest that IL-21 contributes to the ongoing Th1 mucosal response in CD.     

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery. We find that PD-L1 is highly expressed on inflammatory macrophages as compared with resident peritoneal macrophages but can be induced on resident macrophages by classical activation stimuli such as lipopolysaccharide, IFN-gamma, and polyinosinic-polycytidylic acid. Further up-regulation of PD-L1 on inflammatory macrophages can also be induced by subsequent exposure to lipopolysaccharide and IFN-gamma. In contrast, PD-L2 is not expressed on inflammatory macrophages but can be induced by alternative activation via IL-4. Although PD-L1 is highly inducible on a variety of antigen-presenting cell lines as well as resident macrophages, PD-L2 is most significantly inducible only on inflammatory macrophages. PD-L1 up-regulation depends on TLR4 and STAT1, whereas PD-L2 expression depends on IL-4R alpha and STAT6. Consistent with these results, T helper 1T helper 2 (Th1/Th2) cells also differentially up-regulate PD-L1 and PD-L2 expression on inflammatory macrophages. Hence, Th1 cells as well as microbial products can enhance PD-L1 expression on many different macrophage populations, whereas Th2 cells instruct only inflammatory macrophages to up-regulate PD-L2. These results suggest that PD-L1 and PD-L2 might have different functions in regulating type 1 and type 2 responses.     

Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4

Interleukin (IL)-12 plays a critical role in modulating the activities of natural killer (NK) cells and T lymphocytes. In animal models, IL-12 has potent antitumor effects that are likely mediated by its ability to enhance the cytotoxic activity of NK cells and cytotoxic T lymphocytes, and to induce the production of interferon (IFN)-gamma by NK and T cells. In addition to IL-12, NK cells are responsive to IL-2, and may mediate some of the antitumor effects of IL-2. In this study, we examine the interaction between IL-2 and the signaling events induced by IL-12 in NK cells. We find that IL-2 not only up-regulates the expression of IL-12Rbeta1 and IL-12Rbeta2, it also plays an important role in up-regulating and maintaining the expression of STAT4, a critical STAT protein involved in IL-12 signaling in NK cells. In contrast to the effects of IL-2 alone, expression of IL-12 receptors and STAT4 are unaffected or decreased by IL-12 or the combination of IL-2 and IL-12. Through expression of high levels of IL-12 receptors and STAT4, IL-2-primed NK cells show enhanced functional responses to IL-12 as measured by IFN-gamma production and the killing of target cells. NK cells from cancer patients who received low-dose IL-2 treatment also exhibited increased expression of IL-12 receptor chains, suggesting that IL-2 may enhance the response to IL-12 in vivo. These findings provide a molecular framework to understand the interaction between IL-2 and IL-12 in NK cells, and suggest strategies for improving the effectiveness of these cytokines in the immunotherapy of cancer.     

阿奇霉素对博莱霉素致大鼠肺损伤的干预作用及其机制的探讨

目的从Th1/Th2反应平衡消长的方面探讨肺纤维化的发病机制，并继续探讨阿奇霉素对其的干预作用及机制。方法 雄性Wisar大鼠分为博莱霉素模型组，阿奇霉素治疗组和对照组。对苏木精伊红染色（HE）病理结果进行计算机灰度扫描半定量分析，用RNA酶保护实验的方法检测白细胞介素10/γ干扰素（IL-10/IFN-γ）mRNA的表达。结果 （1）气管内给人博莱霉素，使IL-10mRNA/IFN-γmRNA的比例由正常对照绵以IFN-γ为主的Th1优势逆转为以IL-10升高为主的Th2优势。（2）口服阿奇霉素治疗抑制IL-10，IFN-γmRNA在大鼠肺损伤模型中的表达；并于博莱霉素注入后第7天将模型中以IL-10升高为主的Th2优势逆转为IFN-γ为主的Th1优势；从病理上减轻了炎症细胞浸润和肺纤维化程度。结论 （1）致纤维化性肺泡炎早期，在肺泡上皮和基底膜损伤基础上的以IL-10升高为主的Th2优势反应及IFN-γ为主的Th1优势；从病理上减轻了炎症细胞浸润和肺纤维化程度，结论 （1）致纤维化性肺泡炎早期期，在肺泡上皮和基底膜损伤基础上的以IL-10升高为主的Th2优势反应及IFN-γ的相对缺乏，可能起到了促进纤维化形成的作用。（2）阿奇霉素可将博莱霉素致大鼠肺损伤模型中以IL-10升高为主的Th2优势逆转为IFN-γ为主的Th1优势，通过抗炎和免疫调节作用减轻了肺组织炎症损伤和肺纤维化程度。     

Impaired IL-4 and c-Maf expression and enhanced Th1-cell development in Vav1-deficient mice

Although c-Maf is crucial for Th2 differentiation and production of interleukin 4 (IL-4), its regulation is poorly understood. We report that Vav1-/- CD4+ T cells display deficient T-cell receptor (TCR)/CD28-induced IL-4 and c-Maf expression and, conversely, enhanced interferon gamma (IFN-gamma) production and T-bet expression (even when cultured under Th2-polarizing conditions), but intact expression of other Th2 cytokines and GATA-3. Up-regulation of c-Maf was dependent on Ca2+/nuclear factor of activated T cell (NFAT) and, together with IL-4 production, could be rescued in Vav1-/- T cells by Ca2+ ionophore. Deficient IL-4 production was restored by retrovirus-mediated Vav1 expression, but only partially by retroviral c-Maf expression. Similar IL-4 --> IFN-gamma skewing was observed in intact, antigen-primed Vav1-/- mice. Thus, Vav1 is selectively required for IL-4 and c-Maf expression, a requirement reflecting, at least in part, the dependence of c-Maf expression on Ca2+/NFAT signaling.     

Characterization of T-cell clones specific to ovomucoid from patients with egg-white allergy.

BACKGROUND: Allergic reactions to foods are specific problems for infants and young children. Ovomucoid (OM) is one of the major allergens found in egg-white. We previously established several T-cell clones (TCCs) specific to OM in non-polarizing conditions from 4 patients (TM and YN are immediate-type, IH and YT are non-immediate-type) with egg-white allergy. We characterized their reactive epitopes, antigen-presenting molecules (HLA class II), and usage of TCR alpha and beta genes and the CDR3 loop sequence. OBJECTIVE: The objective of this study was to characterize these seven clones (TM 1.3, TM1.4,YN 1.1, YN1.5, IH3.1, IH3.3 and YT6.1) for cytokine production patterns and cell-surface-marker phenotypes. METHODS: We measured the production of cytokines, namely interleukin (IL)-4, IL-5 and interferon-gamma (IFN-gamma) by stimulation with ovomucoid peptides and stained intracellular IL-4 and IFN-gamma, and determined cell-surface markers using anti-interleukin-12 receptor (IL-12R) beta1, anti-IL-12Rbeta2 and anti-interleukin-18 receptor alpha (IL-18Ralpha). RESULTS: Most TCCs secreted both IL-4 and IFN-gamma in response to the OM peptide mixture, but the secretion patterns were variable; an IFN-gamma dominant pattern was seen in IH3.1 andYT6.1, an IFN-gamma>IL-4 pattern in TM1.3 and TM1.4, an IL-4> IFN-gamma pattern in YN1.5. In intracellular IFN-gamma and IL-4 staining, IFN-gamma single-positive cells were predominant in TM1.3, TM1.4, IH3.1 and YT6.1 and IFN-gamma and IL-4 double-positive cells were predominant in YN1.1, YN1.5 and IH3.3. All TCCs were IL-12Rbeta1-positive, and TM1.3, IH3.1, IH3.3 and YT6.1 were both IL-12Rbeta2- and IL-18Ralpha-positive. TM1.4 and YN1.1 were both IL-12Rbeta2- and IL-18Ralpha-negative. Based on these results, TM1.3 and TM1.4, IH3.1 and YT6.1 had a predominantly Th1 character and YN1.1, YN1.5, and IH3.3 possessed a predominantly Th0 character. CONCLUSIONS: The phenotypes of TCCs were not in accordance with their clinical manifestations. TCCs established from patients with immediate-type hypersensitivity had either the Th1 or Th0 phenotype as well as those with non-immediate-type hypersensitivity.     

Cytokine balance in kidney tissue from lupus nephritis patients

OBJECTIVE: To identify the balance of Th1/Th2 cytokine expression in the kidney and evaluate the difference in cytokine balance between patients with lupus nephritis WHO classes IV and V. METHODS: The expression of the CD40 molecule on cultured human mesangial cells was assessed by flow cytometry after stimulation with interferon gamma (IFN-gamma) or other cytokines. Frozen sections of kidney tissue from 10 patients with lupus nephritis and two non-SLE patients (with minimal-change disease) were stained with monoclonal antibodies for interleukin (IL)-4, IL-10, IL-12, IFN-gamma, CD4, CD8, CD40, CD68 and CD40L. RESULTS: CD40 expression of cultured mesangial cells was up-regulated by IFN-gamma, but was not down-regulated in the presence of the Th2 cytokines IL-4 and IL-10. In the glomeruli, CD40 expression and the ratios of IFN-gamma-/IL-10-, IL-12-/IL-4- and (IFN-gamma+IL-12)/(IL-4+IL-10)-positive cells were significantly higher in class IV than in class V lupus nephritis (P < 0.05). Also CD40, IFN-gamma and the activity index derived from the renal biopsy were closely correlated. CONCLUSION: IFN-gamma may contribute to the pathogenesis of proliferative glomerulonephritis by the up-regulation of CD40 and the activation of the cellular immune response in human lupus.